Investigating Therapeutic Potential of Gene Therapy AB-1005 in Moderate Parkinson Disease: The REGENERATE-PD Trial

Parkinson disease (PD) is a progressive neurological condition marked by symptoms like slowed movement, tremors at rest, muscle stiffness, and balance issues. Although current treatments focus on symptom relief, they do not slow or stop disease progression. As a result, there is increasing interest in developing therapies that can modify the course of the disease and enhance quality of life. One promising area of research is gene therapy using adeno-associated viral (AAV) vectors to deliver therapeutic genes directly into the central nervous system.¹